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ABSTRACT 
Background: Incadronate has been found to lessen the increase in cor- 
rected serum calcium levels in malignancy-associated hypercalcemia (MAH) in 
a Phase III study in Japan. The drug is currently used to treat MAH in Japan. 
Objective: The purpose of this study was to assess the clinical usefulness of 
incadronate in patients with MAH. 
Methods: This open-label study was conducted at 3 medical institutions in 
Korea. Korean patients with MAH (corrected serum calcium levels _>11.0 mg/dL) 
were given a single 10-mg IV infusion of incadronate over 2 to 4 hours in 500 to 
1000 mL of normal saline. Corrected calcium levels were determined and subjec- 
tive symptoms and objective findings 0e, bone pain, spontaneous pain, pain from 
contusion, tenderness, other pain, loss of appetite, nausea nd/or vomiting, thirst, 
constipation, fatigue, and disturbance of consciousness) were used to moni- 
tor the effectiveness of the drug for 6 days after the infusion. Symptoms were 
evaluated using a 4-point scale (0 = none to 3 = severe). Adverse events (AFt) were 
identified by patients' reports, and adverse drug events (ADEs) were assessed by 
the investigators throughout the study. 
Results: Twenty-four Korean patients (18 [75%] male, 6 [25%] female; mean 
age, 56.5 years) were included in the study; data from 22 and 24 patients were 
used to assess effectiveness and tolerability, respectively. Corrected serum cal- 
cium level was significantly decreased on day 6 after treatment compared with 
pretreatment on day 0 (baseline) (9.51 [0.89] mg/dL vs 11.83 [0.89] mg/dL; P < 
0.001). The antihypercalcemic effect of incadronate became apparent as an inhi- 
bition of bone absorption a few days after infusion. Corrected serum calcium 
level was significantly decreased on days 2 to 6 (P < 0.001) after treatment corn- 
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pared with pretreatment a  baseline. Evaluation of symptoms showed significant 
improvement in the incadronate-treated group (mean total score [range] at base- 
line, 8 [1-23] and day 6, 5.5 [1-17]; P = 0.001). Eight (33.3%) of the patients were 
found to have ADEs. Some of the 8 patients experienced >1 ADE (mild and transient 
fever [13 events], chills [3], headache [1], and myalgia [1]). AEs were observed in 
19 (79.2%) of 24 patients. The most frequently reported AE was fever (14 events). 
Conclusion: In this small, open-label study, Korean subjects with MAil 
treated with incadronate xperienced significant improvement in symptoms 
and calcium levels from baseline. (Curr Ther Res Clin Exp. 2007;68:193-204) 
Copyright © 2007 Excerpta Medica, Inc. 
Key words: incadronate, bisphosphonate, malignancy-associated hyper- 
calcemia, Korea. 
INTRODUCTION 
Symptoms of malignancy-associated hypercalcemia (MAIl) include anorexia, 
general malaise, nausea, and vomiting, and rapidly aggravating disturbance of 
consciousness and general condition. 1 MAH has an important impact on the 
prognosis of patients and is life-threatening, requiring prompt and appropriate 
treatment. MAH may be caused by local bone resorption due to bone metas- 
tases (local osteolytic hypercalcemia), and production of humoral factors, typi- 
cally parathyroid hormone-related protein from tumors (humoral MAH). About 
80% or more cases of tumor-related hypercalcemia are reportedly humoral 
MAH. 1 Increased bone resorption plays an important role in the onset of both 
types of hypercalcemia. 
Treatment of underlying conditions is the standard for the treatment of 
MAH. 2 Radical treatment of underlying diseases is frequently impossible, how- 
ever, in patients with malignant umors associated with hypercalcemia. 
Hypercalcemia has been symptomatically treated mainly with bisphosphonates 
that inhibit bone resorption. Bisphosphonates are classified according to the 
ratio of calcinations and bone absorption activity into 1 of 3 generations of 
drugs. 3Clodronate is a first-generation bisphosphonate, alendronate is a second- 
generation bisphosphonate, and third-generation drugs include incadronate, 
risedronate, and ibandronate. 2-s 
Among them, incadronate (Astellas Pharma Inc., Tokyo, Japan) was found to 
be 46 times more potent han pamidronate and 11 times more potent (ED~0 IV 
value: incadronate, 0.041 mg/kg vs alendronate, 0.46 mg/kg; and pamidronate, 
1.9 mg) than alendronate in rats with hypercalcemia nduced by parathyroid 
hormone-related peptide, indicating that it possesses potent bone resorption 
inhibitory actions. 6 Japanese clinical studies ~-1° have found that the optimal 
dose of incadronate for MAH is 10 mg. A significant difference was observed 
between the number of patients receiving incadronate and those receiving the 
calcitonin analogue lcatonin with regard to a decrease in serum calcium level 
>1 mg/dL (11/11 vs 6/10, respectively; P < 0.001). 11 A clinical study 12 in Japan 
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found that alendronate was effective for treatment of hypercalcemia n patients 
with malignant tumors (maximum decrease of mean [SD] serum calcium level, 
3.50 [0.81] mg/dL [n = 7] vs elcatonin, 2.21 [1.28] mg/dL [n = 8]; P= 0.04). Another 
study 13 involving pamidronate found similar results (30 mg: 11.98 [0.35] mg/dL 
[n = 17]; 45 mg: 11.12 [0.82] mg/dL [n = 13]; and 60 mg: 11.14 [0.62] mg/dL [n = 
13] significantly lowered serum calcium level dose dependently; all, P < 0.01 vs 
baseline). Incadronate is currently used in the clinical setting in Japan and the 
Philippines. This study examined the efficacy and safety of this bisphosphonate 
in the treatment of MAIl in Korean patients. 
PATIENTS AND METHODS 
This was an open-label, multicenter study carried out at 3 medical institutions 
in Korea. The study protocol was approved by the ethics committees of the 
Samsung Medical Center (Seoul, Korea), the Asan Medical Center (Seoul, 
Korea), and the Korea Cancer Hospital (Seoul, Korea). The nature of the study 
was explained to each patient or guardian before the start of the study, and only 
those who gave written informed consent o participate were enrolled. 
Patients 
We screened cancer patients with MAH aged 25 to 76 years showing 
corrected serum calcium levels _>11.0 mg/dL. Patients were excluded from 
the study for the following reasons: renal dysfunction (ie, serum creatinine 
level >5.0 mg/dL); cardiac diseases within 3 months before the study; a his- 
tory of hypersensitivity o bisphosphonates; easily induced hypersensitivity 
to erythema; asthma or a history of asthma; bisphosphonate reatment with- 
in 8 days of the start of the study; alanine aminotransferase and aspartate 
aminotransferase activities at least 3 times normal; and pregnancy and/or 
breastfeeding. 
Study Drug and Dosing 
Incadronate 10 mg in 5-mL ampoules was used in this study. Patients with a 
corrected serum calcium level >11.0 mg/dL were included in the study. The cor- 
rected serum calcium level was calculated in 1 of the 2 following ways, depend- 
ing on the serum albumin level: (1) for serum albumin >4 g/dL, serum calcium 
level + (4 -  serum albumin level) x 0.8; or (2) for serum albumin _<4 g/dL, the 
measured serum calcium level was used without correction. 14 A single 10-mg IV 
infusion of incadronate was administered to each patient over 2 to 4 hours in 
500 to 1000 mL of normal saline. 
Concomitant Medications 
The following drugs were prohibited during the study period: concomitant 
use of other bisphosphonates or calcitonin. Careful use of the following drugs 
were allowed: (1) corticosteroids if theywere administered >7 days before enter- 
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ing the study (because corticosteroids are known to affect serum calcium lev- 
els, these levels were monitored before enrollment for about 1 week); and 
(2) analgesics, if the initial dosage was used throughout the study period (this 
was done to minimize the influence on the assessment of subjective symptoms 
and objective findings). 
Effectiveness Analysis 
Incadronate infusions were performed at baseline and the patients were 
observed until day 6. At baseline and days 2, 4, and 6, biochemical studies from 
blood and urine samples, observation of subjective symptoms and objective 
findings, and measurement of body temperature, blood pressure, and pulse rate 
were performed. Bone pain, spontaneous pain, pain from contusion, tender- 
ness, other pain, loss of appetite, nausea/vomiting, thirst, constipation, fatigue, 
and disturbance of consciousness were observed as subjective symptoms and 
objective finding. These symptoms were evaluated by a 4-point scale (0 = none 
to 3 = severe) according to the method of Matsumoto et al. 1° 
On day 6, at the end of the observation period, the improvement in the cor- 
rected serum calcium level and the amelioration of subjective symptoms and 
objective findings were evaluated. The degree of improvement in corrected 
serum calcium levels was rated into 3 categories: (1) excellent (normalized to 
<10.4 mg/dL or decreased by >2 mg/dL vs baseline level); (2) good (decreased by 
>1 mg/dL, but not normalized); or (3) poor (decreased by <1 mg/dL, but not nor- 
malized or increased) according to the method of Matsumoto et al. 1° Bone for- 
mation (osteocalcin) and bone resorption markers (deoxypyridinoline and 
amino-terminal N-telopeptide cross-links [NTx] ls,16) were measured in the urine 
at baseline after drug administration and on days 2 and 6. 
Tolerability Analysis 
Clinical symptoms and abnormal laboratory values that occurred by 6 days 
after treatment but had not been observed before the study were regarded as 
adverse events (AEs). All appearances of clinical symptoms were regarded as 
AEs, regardless of potential association to the drug; and clinical symptoms 
related to drug administration were considered to be adverse drug events 
(ADEs). Clinical symptoms were identified by patients' reports (AEs), and ADEs 
were assessed by the investigators. 
Clinical laboratory tests included blood cell counts, hepatic and renal func- 
tion parameters, erum and urine electrolyte levels, and serum parathyroid hor- 
mone levels. Blood samples were taken before treatment and 4 hours after 
observations on day 6. 
For the tolerability analysis, the following serologic tests were performed at 
baseline and day 6: erythrocyte and leukocyte counts, hemoglobin concentration, 
hematocrit, platelet count, y-glutamyltranspeptidase (y-GTP), lactate dehydro- 
genase (LDH), neutrophils, lymphocytes, monocytes, eosinophils, basophils, cho- 
lesterol, and glucose. 
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Statistical Analysis 
All data were collected and analyzed according to the intent-to-treat model. 
A paired ttest was used to compare data between groups before and after treat- 
ment when the data were normally distributed. Data that did not fit the charac- 
teristics for a parametric test were analyzed using the Wilcoxon signed rank 
test. The changes in serum calcium levels, blood pressure, and biochemical and 
urinary parameters before and after treatment were compared using the paired 
t test. Subjective symptoms and objective findings before and after treatment 
were analyzed using the Wilcoxon signed rank test. Global assessments of nor- 
malization of corrected serum calcium level before and after the treatment and 
the incidence of AEs and ADEs were analyzed using the Fisher exact est. P < 0.05 
was defined as statistically significant. 
RESULTS 
A total of 24 patients were enrolled in the study. Among them, 1 patient did not 
meet the inclusion criteria and 1 did not take the study drug. These 2 patients 
were not included in the analysis, and thus, data from 22 patients were used to 
assess efficacy, and data from all 24 patients were used to assess the tolerability. 
Of the 24 patients (18 men, 6 women; mean age, 56.5 years), the most com- 
mon malignancy was esophageal cancer (9 patients), followed by bone metas- 
tases (7). The mean baseline corrected serum calcium level was 12.9 mg/dL. 
Baseline demographic and clinical characteristics of the patients included in the 
efficacy analysis are presented in Table I. All 24 patients were receiving other 
drugs (eg, neuromuscular, alimentary, cardiovascular, hematopoietic, and respi- 
ratory drugs and antibiotics). Bisphosphonates and calcitonins interfered with 
calcium. Seventeen patients had changes een on electrocardiography (ECG) at 
baseline (eg, mild sinus tachycardia [4 patients], sinus bradycardia [2], and 
ventricular hypertrophy [2]), although the changes were not considered clini- 
cally significant and were not related to hypercalcemia. The study investiga- 
tors determined the ECG changes were not related to hypercalcemia. 
Effectiveness Analysis 
Serum Calcium Level 
The time course of the changes in corrected serum calcium levels is shown 
in the figure. After treatment with incadronate, patients howed progressive de- 
creases in corrected serum calcium levels from day 2 to 6, with mean decreases 
of 2.62 and 2.32 mg/dL on days 4 and 6, respectively (mean [SD] baseline, 11.83 
[0.89] mg/dL; day 2, 10.16 [0.93] mg/dL; day 4, 9.21 [0.81] mg/dL; day 6, 9.51 
[0.89] mg/dL; days 2, 4, and 6 vs baseline, P < 0.001). A slowing in the rate of 
increase in serum calcium level was observed in 21 (95.5%) of 22 patients. 
Subjective Symptoms and Objective Findings 
At baseline, thirst, fatigue, and decreased appetite~symptoms related to 
hypercalcemia~were frequently observed. Subjective and objective symptom 
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Table I. Demographic and clinical characteristics of Korean patients with 
malignancy-associated hypercalcemia (N = 24). All data are no. (%) 
except where otherwise noted. 
Characteristic Value 
Sex 
Male 18 (75) 
Female 6 (25) 
Age, mean (SD), y 56.5 (14.0) 
Corrected serum calcium level at screening, mg/dL 
Mean (SD) 12.9 (1.3) 
Range 11.2-1 6.7 
Occurrences of hypercalcemia per week 
Mean (SD), d 17.3 (29.1) 
Range 1-138 
>1 week 11 (45.8) 
1-2 weeks 7 (29.2) 
2-3 weeks 0 
3-4 weeks 2 (8.3) 
>4 weeks 4 (16.7) 
Bone metastasis 7 (29.2) 
Treatment history of bone metastasis 2 (8.3) 
History of anamnesis 23 (95.8) 
Previous medication* 23 (95.8) 
Concomitant medication t 24 (100) 
Abnormal electrocardiogram ~ 17 (70.8) 
*Medications that may have affected serum calcium level. 
tMedications that did not affect serum calcium level. 
~Mild sinus tachycardia, sinus bradycardia, and ST changes were seen on electrocardiog- 
raphy but were not clinically significant or related to hypercalcemia. 
scores decreased after the administration of incadronate---the total score (range) 
at baseline (8.0 [1-23]) was significantly greater than on day 6 (5.5 [1-17]; 
P = 0.001) (Table II). 
Urine Bone Metabolism Markers 
Decreases in levels of both bone metabolism markers~deoxypyridinoline 
(baseline, 13.9 [9.0] pmol/pmol creatinine; day 6, 10.6 [8.0] pmol/pmol creati- 
nine; P < 0.001) and NTx 1~,16 (baseline, 430.0 [738.4] nmol bone collagen equiva- 
lent [BCE]/mmol creatinine; day 6, 317.9 [976.3] nmol BCE/mmol creatinine; 
P < 0.001)~were observed after incadronate treatment (Table liD. The changes 
in urine deoxypyridinoline also showed a significant correlation with changes 
in corrected serum calcium levels (Spearman's correlation coefficient, 0.65; 
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Figure. Mean (SD) serum calcium levels at baseline (day O) and on days 2, 4, and 6 
after administration of a single l O-mg IV infusion of incadronate in Korean 
patients with malignancy-associated hypercalcemia (n = 22). *P < 0.001 versus 
baseline. 
P = 0.008). On the other hand, the bone formation marker osteocalcin was not 
affected by incadronate administration (baseline, 30.0 [21.0] ng/mL vs day 6, 
28.1 [24.6] ng/mL). 
Tolerab i l i ty  Analysis 
Clinical Symptoms 
Eighteen ADEs were observed in 8 (33.3%) of 24 patients (Table IV). These 
events included mild fever (13 patients), chills (3), headache (1), and myalgia 
(1), all of which developed on the day of the infusion and disappeared by day 4. 
On the other hand, AEs regardless of association to the drug were observed in 
19 (79.2%) of 24 patients. A total of 66 symptom events (eg, fever [14 patients], 
myalgia [4], headache [3], dyspnea [3], hyperglycemia [3], and others [39]) were 
reported. 
Clinical Laboratory Data 
Significant increases occurred in serum activities on day 6 compared with 
baseline for both LDH (571.2 [322.5] IU/L vs 449.3 [199.9] IU/L; P= 0.012) and 
y-GTP (106.0 [104.2] IU/L vs 76.3 [81.0] IU/L; P = 0.004). Significant decreases 
were seen on day 4 compared with baseline in both serum creatinine level 
(0.88 [0.25] mg/dL vs 0.96 [0.22] mg/dL; P = 0.001) and serum alkaline phos- 
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Table II. Changes in subjective and objective symptom scores after a single l O-mg IV 
infusion of incadronate at baseline in Korean patients with malignancy- 
associated hypercalcemia (intent-to-treat) (n = 22). All data are median 
(range). 
Subjective and Objective Symptom Score* 
Symptom Baseline Day 2 Day 4 Day 6 
Spontaneous pain I (0-3) I (0-3) I (0-2) I (0-3) 
Pain from contusion 0 (0-I) 0 (0-I) 0 (0-I) 0 (0-I) 
Tenderness 0 (0-3) 0 (0-2) 0 (0-2) 0 (0-2) 
Bone pain 0 (0-3) 0 (0-2) 0 (0-2) 0 (0-2) 
Other pain I (0-3) 0.5 (0-3) I (0-3) 0.5 (0-3) 
Loss of appetite I (0-3) 1.5 (0-3) I (0-3) I (0-3) 
Nausea/vomiting 0 (0-2) 0 (0-2) 0 (0-2) 0 (0-2) 
Excessive thirst I (0-2) 1 (0-2) I (0-2) 0 (0-2) 
Constipation I (0-2) I (0-2) I (0-2) 0 (0-2) 
Fatigue I (0-2) I (0-2) I (0-2) I (0-2) 
Disturbance of consciousness 0 (0-3) 0 (0-0) 0 (0-0) 0 (0-0) 
Other 0 (0-I) 0 (0-I) 0 (0-I) 0 (0-I) 
Total score 8 (I-23) 7.5 (I-15) 6 (2-14) 5.5 ( I - I  7) 
pt 0.053 0.008 0.001 
*Each symptom was assessed on a 4-point scale (0 = none to 3 = severe). 
fDifference in total score between baseline and each of days 2, 4, and 6 (Wilcoxon signed rank test). 
Table III. Urine excretion values of electrolytes, creatinine, and bone metabolism mark- 
ers at baseline, and 2 and 6 days after the administration of a single l O-mg IV 
infusion of incadronate in Korean patients with malignancy-associated hyper- 
calcemia (intent-to-treat) (N = 24). All data are mean (SD). 
Urine Excretion Value 
Baseline Day 2 Day 6 P* 
Calcium, mg/g creatinine 
Phosphate, mg/g creatinine 





496.7 (355.2) 204.1 (130.7) 190.2 (155.4) <0.001 
539.5 (292.4) 311.6 (209.6) 460.0 (317.4) 0.283 
1 22.8 (62.8) 98.1 (53.1) 1 28.7 (70.2) 0.836 
707.6 (260.2) 794.0 (295.0) 740.5 (267.9) 0.326 
13.9 (9.0) 10.2 (7.4) 10.6 (8.0) <0.001 
430.0 (738.4) 129.8 (322.3) 317.9 (976.3) <0.001 
NTx = amino-terminal N-telopeptide cross-links. 
*Baseline versus day 6. 
tnmol bone collagen equivalent/mmol creatinine. 
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Table IV. Rate of adverse events (AEs) after administration of a single l O-mg 
IV infusion of incadronate in Korean patients with malignancy- 
associated hypercalcemia (intent-to-treat) (N = 24). 
Patients, no. (%) Cases, no. (%) 
(N = 24) (N = 66) 
AEs 19 (79.17) 66 (100) 
Adverse drug reactions 8 (33.33) 18 (27.27) 
Serious AEs 2 (8.33) 2 (3.03) 
phatase (ALP) activity (158.54 [150.04] mU/mL vs 176.29 [318.70] mU/mL; P = 
0.032). Serum creatine kinase activity increased significantly on day 6 compared 
with baseline (51.75 [42.46] mg/dL vs 36.43 [46.56] mg/dL; P = 0.017). 
There were no abnormal changes in clinical laboratory values (ie, erythro- 
cyte count, hemoglobin level, hematocrit, platelet count, leukocyte count, 
neutrophils, lymphocytes, monocytes, eosinophils, basophils, cholesterol, 
and glucose) that could be causally related to administration of the study 
medication (data not shown; N = 24). 
Serum Electrolyte Levels 
A transient significant decrease of serum phosphate concentration on day 4 
compared with baseline level (2.04 [0.56] mg/dL vs 2.69 [0.54] mg/dL; P= 0.006) 
was observed after incadronate treatment. A significant increase in serum mag- 
nesium level was seen on day 6 compared with baseline (2.21 [0.28] mg/dL vs 
1.98 [0.32 ] mg/dL; P < 0.001) (Table V). 
Urine Electrolyte and Creatinine Excretion 
Incadronate was associated with significantly decreased urine calcium excre- 
tion on day 6 compared with baseline level (190.2 [155.4] mg/g creatinine vs 
496.7 [355.2] mg/g creatinine; P < 0.001). No significant changes were observed 
in levels of urine magnesium, phosphate, or creatinine after administration of
incadronate (Table lll). 
DISCUSSION 
We found that treatment with incadronate lowered the increased calcium level 
in Korean patients with MAH; these findings support the results obtained in 
Japanese patients. 8,1° Calcium levels were improved at the first assessment on 
day 2 after incadronate administration, and improvements continued for 6 days 
after dosing. These findings suggest hat there may be no racial differences in 
the effectiveness of this drug among different groups of Asian patients. 
Nakamura et al 1T and Usui et a118 reported that after the IV administration of
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Table V. Mean (SD) serum electrolyte levels at baseline (day O) and 2, 4, and 6 days 
after the administration of a single lO-mg IV infusion of incadronate in 
Korean patients with malignancy-associated hypercalcemia (intention-to-treat 
model) (N = 24). 
Electrolyte Baseline Day 2 Day 4 Day 6 P* 
Phosphate, 
mg/dL 2.69 (0.54) 2.20 (0.48) 2.04 (0.56) 2.35 (0.58) 0.006 
Sodium, 
mmol/L 138.8 (4.1) 37.4 (3.7) 137.3 (4.5) 137.5 (3.8) 0.083 
Potassium, 
mmol/L 4.08 (0.66) 3.93 (0.73) 4.14 (0.99) 4.20 (0.55) 0.522 
Chloride, 
mmol/L 102.5 (3.3) 101.5 (3.3) 103.0 (2.8) 102.9 (3.9) 0.776 
Magnesium, 
mg/dL 1.98 (0.32) 1.99 (0.32) 2.17 (0.33) 2.21 (0.28) <0.001 
*Baseline versus day 6. 
14C-incadronate 0.3 mg/kg to rats and dogs, the unchanged rug appeared in 
urine and bone without any metabolites. These findings were similar to those 
seen with autoradiography, suggesting that the drug does not undergo metabo- 
lism and may therefore not be subject to racial differences among patients. 1T 
The calcium level normalization rate of incadronate was higher (95.5% [21/ 
22 patients]) than the results (81.8% [9/11]) obtained in another study. 1° 
Incadronate may decrease serum calcium levels by inhibiting bone absorption, 
causing decreases in urine levels of deoxypyridinoline/creatinine a d NTx, 
which are markers of bone metabolism. 1° 
Various objective and subjective symptoms (eg, excessive thirst, constipa- 
tion, and fatigue) were significantly ameliorated after the administration of in- 
cadronate to these patients. This effectiveness may be related to the normali- 
zation of calcium levels; a Japanese Phase III study found a close relationship 
between the changes in corrected serum calcium levels and subjective and 
objective symptoms. 1°These improvements may also be associated with the 
resolution of dehydration. In addition, there may be a relationship between 
serum calcium levels and renal dysfunction. Therefore, normalization of cal- 
cium levels might be due to inhibition of bone absorption, but the resolution of 
dehydration or renal dysfunction cannot be disregarded for normalization of 
calcium levels. 
The increases in LDH and y-GTP activities and the decrease in AlP activity seen 
after the administration of incadronate were presumably due to progression of 
the original disease. The increases in creatinine levels and creatine kinase 
activity were within the normal ranges and were not clinically significant. Thus, 
no abnormal responses related to incadronate administration were observed. 
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A significant correlation was found between changes in corrected serum cal- 
cium and phosphate levels after treatment with incadronate (Spearman's corre- 
lation coefficient, 0.52; P = 0.021) in a Japanese Phase III study. 1° The changes 
we observed in serum phosphate and magnesium levels may have been due to 
incadronate therapy. 
The rate of the ADEs (eg, fever, chills, muscle pain, and headache) after 
administration of the drug was 33.3% (8/24 patients), but the symptoms were 
mild and transient. In a Japanese Phase III study, ~° the rate of ADEs was 25.0% 
(3/12 patients). 
Study Limitations 
Incadronate has been shown to ameliorate the increase in corrected serum 
calcium levels in MAH in a Japanese Phase III study.l° The drug is currently used 
for the treatment of MAH in Japan. This was an open-label study that did not 
include a control group and used a small number of patients as a preliminary 
clinical trial. Thus, further investigations may be necessary to confirm these 
findings. 
CONCLUSION 
In this small, open-label study, Korean subjects with MAH treated with in- 
cadronate xperienced significant improvement in symptoms and calcium levels 
from baseline. 
REFERENCES 
1. Muggia FM. Overview of cancer-related hypercalcemia: EpJdemiology and etiology. 
Semin Oncol. 1990;17(Suppl 5):3-9. 
2. Fleisch H. Bisphosphonate: Mechanism of action and clinical applications. In: Peck 
WA, ed. Bone and Mineral Research. Annual 1. New York, NY: Elsevier Science Pub. 
Co; 1982:319-357. 
3. Hotte S J, Webert KE, Major PP. Zoledronic acid: An overview of its current and poten- 
tial benefits in patients with malignancy. Todays Therapeutic Trends. 2002;20:197- 
219. 
4. Boonekamp PM, Lowik CW, van der Wee-Pals L J, et al. Enhancement ofthe inhibitory 
action of APD on the transformation f the osteoclast precursors into resorbing cells 
after dimethylation of the amino group. Bone Miner. 1987;2:29-42. 
5. Boonekamp PM, van der Wee-Pals L J, van Wijk-van Lennep MM, et al. Two modes of 
action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone 
Miner. 1986;1:27-39. 
6. Takahashi K, Fukushima S, Kokubo S, et al. Effect of YM175 on hypercalcemia 
induced by human oral squamous cell carcinoma cells On Japanese, English 
abstract). Kurinikaru Sutadi (Clinical Study). 1994;28:83-97. 
7. Ogata E, Tel M. Phase I clinical study of YM175, a new bone resorption inhibitor, by 
single intravenous administration i  healthy male adults. Jpn Pharmacol Ther. 1994; 
22:181-210. 
203 
CURRENT THERAPEUTIC RESEARCH 
8. Matsumoto T,Takebe K, Onaya T, et al. Early phase II study of YM175 in patients with 
malignancy-associated hypercalcemia On Japanese). Shindan To Chiryo. 1994;82: 
153-165. 
9. Matsumoto T,Takebe K, Ishii J, Nagata N. Dose finding study of YM175 in malignancy- 
associated hypercalcemia. Jpn J Clin Exp Med. 1994;71:237-254. 
10. Matsumoto T, Nagata N, Horikoshi N, et al. Comparative study of incadronate and 
elcatonin in patients with malignancy-associated hypercalcaemia. J lnt Ailed Res. 2002; 
30:230-243. 
11. Thiebaud D, Jacquet AF, Burckhardt P. Fast and effective treatment of malignant 
hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 
3-amino 1-hydroxypropylidene- 1-bisphosphonate. Arch Intern Med. 1990; 150:2125-2128. 
12. Sato M, Hattori M, Tomita A, et al. Comparative clinical study of alendronate injec- 
tion with elcatonin in malignancy-associated hypercalcemia p tients. Rinshou lyaku. 
1994;10:2667-2689. 
13. Matsumoto T, Fujlta T, Morll H, et al. Dose finding studies of pamidronate dlsodium 
in malignancy-associated hypercalcemia p tients. Rinshou lyaku. 1992;8:605-629. 
14. Portale AA. Blood calcium, phosphorus and magnesium. In: Favus M J, ed. Primer on 
the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Philadelphia, Pa: 
Lippincott, Williams & Willdns; 1999:115-118. 
15. Tsai KS, Hsu SH, Yang RS, et al. The effectiveness of cyclic and continuous oral 
clodronate therapy on bone density and markers in osteopenic postmenopausal 
women. Calcif Tissue Int. 1999;64:384-388. 
16. Hanson DA, Wets MA, Bollen AM, et al. A specific immunoassay for monitoring 
human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides 
in urine. J Bone Miner Res. 1992;7:1251-1258. 
17. Nakamura E, Imazaki H, Usui T, et al. Metabolism of YM175. Distribution and excretion 
by intravenous administration f 14C-YM175 in rats. Yakubutsu Taisha. 1995;9:835-847. 
18. Usui T, Watanabe T, Higuchi S. Determination of a new bisphosphonate, YM175, in 
plasma, urine and bone by high-performance liquid chromatography with electro- 
chemical detection. J Chromatogr. 1992;584:213-220. 
Address correspondence to: Keunchil Park, MD, Division of Hematology and 
Oncology, Department of Internal Medicine, Samsung Medical Center, 
Sungkyunkwan University School of Medicine, 50 Ilwon-dong, Kangnam-gu, Seoul 
135-710, Korea. E-mail: kpark@smc.samsung.co.kr 
204 
